Contact
Please use this form to send email to PR contact of this press release:
Retrophin Doses First Patient in Pivotal Phase 3 PROTECT Study of Sparsentan for the Treatment of IgA Nephropathy
TO:
Please use this form to send email to PR contact of this press release:
Retrophin Doses First Patient in Pivotal Phase 3 PROTECT Study of Sparsentan for the Treatment of IgA Nephropathy
TO: